A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Study sponsor: Eloxx Pharmaceuticals, Inc. · ELOX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-04-06Actual
Enrollment · participants17Actual
Source updated2023-08-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.